Dryvax Dilution-Prev Vacc Adults

This study has been completed.
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
First received: March 28, 2002
Last updated: August 26, 2010
Last verified: May 2006

A double-blind, randomized, dose-response study of four dilutions of Dryvax in previously vaccinated adults in order to assess the clinical success rates, humoral responses, and virus-specific actifity of cytotoxi T cells and interferon-y producing T cells

Condition Intervention Phase
Biological: Dryvax
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults

Resource links provided by NLM:

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 90
Study Start Date: April 2004
Estimated Study Completion Date: November 2004


Inclusion Criteria:

  • For cohort E (never vaccinated): Aged 18-31; Never been vaccinated for smallpox.
  • If female, not pregnant or lactating.
  • Promise to use an effective method of birth control for 7 months after vaccination.
  • Negative result on a test for HIV, AIDS, Hepatitis B and C.
  • Acceptable as blood donors.
  • For cohorts A, B, C, D (previously vaccinated): Aged 32 to 60 years; known history of smallpox vaccination with a typical vaccinia scar; no smallpox vaccination after 1971.
  • Healthy adults (aged 18-60).

Exclusion Criteria:

  • Eczema or history of eczema, or other chronic skin disorder.
  • Pregnancy or lactation.
  • History of immunodeficiency, liver disease, severe kidney impairment, malignancy, HIV, Hepatitis B, or Hepatitis C.
  • Household contact with persons who are under 12 months of age, pregnant or lactating, or have any of the specified diseases.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032708

United States, Missouri
Saint Louis University Health Sciences Center
St. Louis, Missouri, United States, 63110-0250
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00032708     History of Changes
Other Study ID Numbers: 01-651
Study First Received: March 28, 2002
Last Updated: August 26, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Blood Group Incompatibility
Brain Diseases
Brain Diseases, Metabolic
Central Nervous System Diseases
DNA Virus Infections
Erythroblastosis, Fetal
Hematologic Diseases
Immune System Diseases
Infant, Newborn, Diseases
Metabolic Diseases
Nervous System Diseases
Pathologic Processes
Poxviridae Infections
Virus Diseases

ClinicalTrials.gov processed this record on October 02, 2015